American trypanososmiasis and Leishmaniasis are relevant public health problems in Ibero America. The in vitro antiparasitic activity of barks and leaves extracts of Erythrina crista-galli L., E. dominguezii Hassl and E. falcate Benth was evaluated on Trypanosoma cruzi tripomastigotes forms and Leishmania amazonensis, L. infantum and L. braziliensis promatigotes. The IC50s of the bark extract of E. dominguezii Hassl with two T. cruzi strains, Ypsilon and Cl Brener, were 11.7 µg/ml and 14.9 µg/ml. Leaf extract showed IC50 higher than 250 µg/ml. Bark extract of E. falcate Benth had IC50s of 11.29 µg/ml and 7.37 µg/ml with Ypsilon and Cl Brener strains and its leaf extract showed IC50s of 37.2 µg/ml and 25.68 µg/ml. Leaf extract of E. crista-galli L. showed IC50 higher than 250 µg/ml while bark extract had IC50s of 11.2µg/ml and 7.1 µg/ml with Ypsilon and Cl Brener strains. Bark extract of E. dominguezii Hassl showed IC50s of 3.22 µg/ml 6.94 µg/ml and 1.9 µg/ml for L. amazonensis, L. infantum and L. braziliensis and in leaf extract IC50 was higher than 100 µg/ml. Bark extract of E. crista-galli L. had IC50s of 2.1 µg/ml, 2.09 µg/ml and 1.6 µg/ml for the three species. Its leaf extract had IC50 higher than 100 µg/ml. Bark extracts of E. falcate Benth had IC50s of 2.17 µg/ml, 2.09 µg/ml and 1.52 µg/ml with the three Leishmania species and the leaf extract showed IC50s of 14.9 µg/ml, 10.4 µg/ml and 11.6µg/ml. Bark extracts could be an alternative for the treatment of these parasitic diseases previous confirmation by in vivo and toxicity studies.
La tripanosomiasis americana y la leishmaniosis son problemas de salud pública relevantes en Iberoamérica. Se evaluó la actividad antiparasitaria in vitro de extractos de cortezas y hojas de Erythrina crista-galli L., E. dominguezii Hassl y E. falcata Benth sobre formas tripomastigotas de Trypanosoma cruzi y promastigotas de Leishmania amazonensis, L. infantum L. braziliensis. El extracto de corteza de E. dominguezii Hassl presentó CI50 de 11,7 µg/ml y 14,9 µg/ml con dos cepas de T. cruzi, Ypsilon y Cl Brener. El extracto de hoja presentó CI50 mayor a 250 µg/ml. La corteza de E. falcata Benth tuvo CI50 de 11,29 µg/ml y 7,37 µg/ml con Ypsilon y Cl Brener y el extracto de hojas CI50 de 37,2 µg/ml y 25,68 µg/ml. El extracto de hojas de E. crista-galli L. presentó CI50 mayor a 250 µg/ml, y el de corteza CI50 11,2µg/ml y 7,1µg/ml con Ypsilon y Cl Brener. El extracto de corteza de E. dominguezii Hassl presentó CI50 de 3,22 µg/ml, 6,94 µg/ml y 1,9 µg/ml para L. amazonensis, L. infantum y L. braziliensis y en hojas la CI50 fue mayor a 100 µg/ml. La corteza de E. crista-galli L. tuvo CI50 de 2,1 µg/ml, 2,09 µg/ml y 1,6 µg/ml para las tres especies. El extracto de hoja tuvo una CI50 mayor a 100 µg/ml. El extracto de corteza de E. falcata Benth tuvo CI50 de 2,17 µg/ml, 2,09 µg/ml y 1,52 µg/ml con las tres especies de Leishmania y el de hoja CI50 de 14,9 µg/ml, 10,4 µg/ml y 11,6 µg/ml. Los extractos de corteza podrían ser una alternativa para el tratamiento de estas enfermedades parasitarias, previa confirmación con estudios in vivo y toxicidad.